Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGIOS PHARMACEUTICALS, INC. Director's Dealing 2021

Jan 25, 2021

31580_dirs_2021-01-25_d70d6a5a-e88d-4dda-a117-46fa7669cfe4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-01-16

Reporting Person: Miles Darrin (Chief Commercial Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common stock 5875 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock options (right to buy) $110.91 2025-08-03 Common stock (30000.0) Direct
Stock options (right to buy) $39.76 2026-02-16 Common stock (521.0) Direct
Stock options (right to buy) $50.4 2027-02-21 Common stock (12338.0) Direct
Stock options (right to buy) $77.7 2028-02-16 Common stock (11060.0) Direct
Stock options (right to buy) $58.86 2029-02-22 Common stock (8690.0) Direct
Stock options (right to buy) $51.51 2030-02-14 Common stock (35000.0) Direct
Restricted stock units $ Common stock (922.0) Direct
Restricted stock units $ Common stock (1449.0) Direct
Restricted stock units $ Common stock (26000.0) Direct

Footnotes

F1: This option was granted on August 3, 2015. The shares underlying this option are fully vested.

F2: This option was granted on February 16, 2016. The shares underlying this option are fully vested.

F3: This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F4: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F5: This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F6: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F7: The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F8: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F9: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

F10: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.